Abstract YO32
Case summary
Prostatic rhabdomyosarcoma in adult is a uncommon disease of adult. There are few cases reported as adult rhabdomyosarcoma of prostate. Most of the cases present with advanced stage. Modality of treatment vary from that of pediatric counterpart. Moreover stage wise treatment for adult disease are not well defined. We presented a young adult case of rhabdomyosarcoma presented with acute retention of urine and severe lower abdominal pain. After evaluation we thought of prostatic rhabdomyosarcoma which was later confirmed by IHC study. As the case was metastatic during presentation panel of experts recommend neoadjuvant chemotherapy followed by surgery according to the response of the treatment. There is no clear treatment plan recommendation for this advance stage, but we planned to evaluate Doxorubicin and Ifosphamide regimen for clinical trial. Surprisingly the systemic therapy works and after 3 cycle there was a very small residue persist. After almost complete response we recommended to continue further 3 cycle. Though surgery and radiation therapy Is the mainstay of treatment we can recommend neoadjuvant chemotherapy for metastatic rhabdomyosarcoma of prostate in adult from our clinical experience.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
164P - Multi-centered phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502)
Presenter: Yusuke Sasaki
Session: Poster display session
Resources:
Abstract
165P - Lenvatinib treatment for advanced hepatocellular carcinoma: The relationship between efficacy and safety
Presenter: Takayoshi Oikawa
Session: Poster display session
Resources:
Abstract
166P - The comparison between UGT1A1 single heterozygous and wild type regarding the clinical outcomes of fixed dose irinotecan monotherapy for advanced gastric cancer: Multicenter retrospective study
Presenter: Takahide Sasaki
Session: Poster display session
Resources:
Abstract
167P - Prognostic impact of the C-reactive protein/albumin ratio in advanced pancreatic cancer treated with GEM plus nab-PTX or FOLFIRINOX: Based on the results of a multicenter retrospective study (the NAPOLEON study)
Presenter: Akitaka Makiyama
Session: Poster display session
Resources:
Abstract
168P - A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of Glasgow Prognostic Score (GPS)
Presenter: Takuya Honda
Session: Poster display session
Resources:
Abstract
169P - M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signalling pathways
Presenter: Yizhuo Wang
Session: Poster display session
Resources:
Abstract
170P - Surgery alone versus surgery combined with Chemotherapy: Survival patterns among patients with fibrolamellar hepatocellular carcinoma
Presenter: Yasmine Ashraf
Session: Poster display session
Resources:
Abstract
171P - The clinical value of prognostic nutritional index in patients with anastomotic leakage after minimally invasive esophagectomy
Presenter: Yan Wang
Session: Poster display session
Resources:
Abstract
172P - Preoperative neutrophil‐to‐lymphocyte ratio (NLR) predicts recurrence after surgery in patient with pancreatic neuroendocrine neoplasm (PanNEN)
Presenter: Takayuki Miura
Session: Poster display session
Resources:
Abstract
173P - Cancer stem-like phenotypes including immune surveillance and its responsible genes in induced liver cancer stem-like cells
Presenter: Ryouichi Tsunedomi
Session: Poster display session
Resources:
Abstract